Synapse - David Ilson

Search Within

David H Ilson

Results (100)

Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma

Journal Article

Gerber, N.; Ilson, D. H.; Wu, A. J.; Janjigian, Y. Y.; Kelsen, D. P.; Zheng, J.; Zhang, Z.; Bains, M. S.; Rizk, N.; Rusch, V. W.; more...
Diseases of the Esophagus (2014)

Fulltext@MSK | Save

Phase II study of preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in patients with locally advanced gastric and GEJ adenocarcinoma

Meeting Abstract

Won, E.; Ilson, D.; Kelsen, D. P.; Strong, V. E.; Schoder, H.; Janjigian, Y. Y.; Shah, M. A.; Coit, D. G.; Brennan, M. F.; Capanu, M.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and prolonged stable disease observed in adenocarcinoma

Meeting Abstract

Ku, G. Y.; Janjigian, Y. Y.; Shah, M. A.; Herrera, J.; Tang, L. H.; Fuqua, L.; Capanu, M.; Ilson, D.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in locally advanced gastroesophageal junction and gastric adenocarcinoma

Meeting Abstract

Ku, G. Y.; Kelsen, D. P.; Strong, V. E.; Schöder, H.; Janjigian, Y. Y.; Shah, M. A.; Coit, D. G.; Brennan, M. F.; Capanu, M.; Ilson, D. H.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer

Meeting Abstract

Janjigian, Y. Y.; Capanu, M.; Gromisch, C. M.; Kelsen, D. P.; Ku, G. Y.; Brown, K. T.; Schattner, M.; Ilson, D. H.; Solit, D. B.; Berger, M. F.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma

Meeting Abstract

Ilson, D.; Goodman, K. A.; Janjigian, Y. Y.; Shah, M. A.; Kelsen, D. P.; Rizk, N. P.; Rusch, V. W.; Wu, A. J. C.; Campbell, J.; Capanu, M.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma

Meeting Abstract

Ilson, D.; Goodman, K. A.; Janjigian, Y. Y.; Shah, M. A.; Kelsen, D. P.; Rizk, N. P.; Rusch, V. W.; Wu, A. J. C.; Campbell, J.; Capanu, M.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer

Journal Article

Ilson, D. H.; Minsky, B. D.; Ku, G. Y.; Rusch, V.; Rizk, N.; Shah, M.; Kelsen, D. P.; Capanu, M.; Tang, L.; Campbell, J.; more...
Cancer (2012)

Fulltext@MSK | Save

Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease observed in adenocarcinoma

Meeting Abstract

Ilson, D.; Janjigian, Y. Y.; Shah, M. A.; Kelsen, D. P.; Tang, L. H.; Campbell, J.; Fuqua, L.; Capanu, M.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

Journal Article

Shah, M. A.; Power, D. G.; Kindler, H. L.; Holen, K. D.; Kemeny, M. M.; Ilson, D. H.; Tang, L.; Capanu, M.; Wright, J. J.; Kelsen, D. P.
Investigational New Drugs (2011)

Fulltext@MSK | Save